The FDA is stepping in to prevent a potential shortage of a product that keeps the most fragile newborns alive: neonatal “starter” parenteral nutrition (PN).
Parenteral nutrition delivers essential nutrients intravenously to premature and critically ill newborns who can’t yet be fed by mouth or feeding tube. The agency acted after children’s hospitals raised alarms about continued access, prompted by the discontinuation of certain standardized neonatal starter PN products made by two outsourcing facilities that are permanently closing.
What the FDA is doing
The FDA says it is deploying regulatory tools to address the supply-chain gap and maintain access to these life-saving products for vulnerable newborn populations. (The agency didn’t detail every mechanism in its announcement.)
Why it matters
For a premature baby, even a brief interruption in IV nutrition can be dangerous, and neonatal PN is a specialized product with few suppliers — so the loss of two facilities is a serious vulnerability. It’s a reminder that drug and medical-product shortages hit hardest at the margins, where patients (here, newborns) have no alternative and little slack. Proactive FDA action to shore up supply before a gap opens is exactly the kind of intervention these situations call for.